Back to Market返回行情

NTRA Natera, Inc.

USHealthcare
$281.85+2.72%ClosedMarket Cap: $40.37B

As of 2026-07-09 16:00

Why NTRA matters now

Natera, Inc. (NTRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $281.85 with +2.72% on the session and $40.37B in market capitalization; recent performance reads 1-month +18.04% and YTD +1.01%.

The latest financial table shown here is Q1 2026, with revenue of $696.6M, net income of $-85.1M, and EPS of $-0.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 0.3%.

The latest indexable market news headline is "Why Investors Need to Take Advantage of These 2 Medical Stocks Now" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Buy with a median target of $267.50; recent insider activity includes Chapman Rowan E filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

PEG

P/B

18.46

P/S

13.25

EV/EBITDA

-144.32

DCF Value

$-331.66

FCF Yield

0.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

65.2%

Operating Margin

-13.0%

Net Margin

-9.0%

ROE

-15.1%

ROA

-8.7%

ROIC

-11.9%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$696.6M$-85.1M$-0.60
Q4 2025$665.5M$47.3M$0.35
FY 2025$2.31B$-208.2M$-1.52
Q3 2025$592.2M$-87.5M$-0.64

Analyst Ratings

Consensus

Buy

Target (Consensus)

$259.88

Target (Median)

$267.50

Target Range

$220.00 - $285.00

Strong Buy: 5Buy: 13Hold: 3Sell: 0Strong Sell: 0
Goldman SachsNeutral
2026-06-05
BTIGBuy
2026-05-11
Wells FargoEqual Weight
2026-05-08
JP MorganOverweight
2026-05-08
Evercore ISI GroupOutperform
2026-05-08

Trading Activity

Insider Trades

Chapman Rowan Edirector
Sell2026-06-17
Sheena Jonathandirector, other: CO-FOUNDER
Sell2026-06-17
Sheena Jonathandirector, other: CO-FOUNDER
Sell2026-06-17
Sheena Jonathandirector, other: CO-FOUNDER
Sell2026-06-17
Sheena Jonathandirector, other: CO-FOUNDER
Sell2026-06-17

Company Info

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Country

US

Exchange

Beta

1.54

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.